Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab ...

Psoriasis is a long-term disease that affects the immune system. It makes skin cells grow too fast. Instead of new cells ...

Health experts reveal the impact of the inflammatory skin condition on joints, and highlight symptoms and management tips ...

The inspiration for her business, which is called Granlab, came from watching her grandmother experience excruciating ...

There’s no such thing as one-size-fits-all when it comes to a skincare routine – particularly those of us with skin ...

APREMILAST demonstrated sustained efficacy and a consistent safety profile over 52 weeks in paediatric patients with moderate ...

Patients with severe psoriasis who were treated with TNFi long-term had a lower risk of developing PsA than those treated with phototherapy.

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Net loss narrowed significantly, with GAAP earnings per share of $(0.13) in Q2 2025, GAAP EPS of $(0.13) in Q2 2025 exceeded analysts' estimate of $(0.22) by $0.35. GAAP revenue was $0.1 million in Q2 ...

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and ...